Clinical trial • Phase I | Phase II • Immunology

fisetin for Healthy volunteers | Multimorbidity

Phase I | Phase II trial of fisetin for Healthy volunteers | Multimorbidity. 60 participants.

Overview

Trial Therapeutic Area
Immunology
Trial Disease
Healthy volunteers | Multimorbidity
Trial Stage
Phase I | Phase II
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
12-12-2023
First CTIS Authorization Date
26-03-2024

Trial design

Phase I | Phase II trial across 1 site in Denmark.

Target Sample Size
60

Eligibility

Recruits 60 No vulnerable population selected.

Vulnerable Population
No vulnerable population selected

Recruitment

Planned Sample Size
60
Recruitment Window Months
30

Geography

Total Number Of Sites
1
Total Number Of Participants
60

Denmark

Earliest CTIS Part Ii Submission Date
15-03-2024
Latest Decision Or Authorization Date
04-07-2025
Processing Time Days
476
Number Of Sites
1
Number Of Participants
60

Sites

Site Name
Hvidovre Hospital
Department Name
Department of Clinical Research
Principal Investigator Name
Ove Andersen
Principal Investigator Email
ove.andersen@regionh.dk
Contact Person Name
Ove Andersen
Contact Person Email
ove.andersen@regionh.dk
Number Of Participants
60

Sponsor

Primary sponsor

Full Name
Hvidovre Hospital
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Investigational products

Investigational Product Name
fisetin
Active Substance
fisetin
Modality
Small molecule

Related trials

Other published trials that may interest you.